InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Wednesday, 05/22/2019 8:40:40 AM

Wednesday, May 22, 2019 8:40:40 AM

Post# of 48316
News: $ONCS OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer

SAN DIEGO and PENNINGTON, N.J. , May 22, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a late-stage cancer biotechnology company developing gene-based intratumoral immunotherapies, today announces interim data from KEYNOTE-890, an ongoing Phase 2 study of TA...

In case you are interested https://marketwirenews.com/news-releases/oncosec-provides-encouraging-interim-data-from-ongoing-keynote-890-study-of-tavo-in-combination-with-keytruda-xae-for-the-treatment-of-heavily-pretreated-chemotherapy-radiotherapy-refractory-metastatic-triple-negative-breast-cancer-8228844.html